San Francisco Bay Area biotech stories.
Wednesday, September 26, 2012
Third Rock biotech startups find work-share partner in Cytokinetics
Cytokinetics' Robert Blum.
There's a line of thought in the cash-sucking biotech world that once a small company gets a drug into the clinic -- especially if investors want to accelerate their return -- that it winds down research operations. Robert Blum doesn't buy it.
Instead, the president and CEO of
(NASDAQ: CYTK) has discovered a way to help pay for his research staff while awaiting the results of a handful of clinical trials: Rent out their expertise.
Share to Twitter
Share to Facebook
Share to Pinterest
Global Blood Therapeutics
Post a Comment
Post Comments (Atom)